3 unchanged sentences
The Chief Executive Officer, Robert B.
−Removed: Ford, and the Chief Financial Officer, Robert E.
−Removed: Funck, Jr., evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Commission under the Securities Exchange Act of 1934 (the Exchange Act) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
+Added: Ford, and the Chief Financial Officer, Philip P.
+Added: Boudreau, evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Commission under the Securities Exchange Act of 1934 (the Exchange Act) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Internal Control Over Financial Reporting
8 unchanged sentences
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
−Removed: Incorporated herein by reference are “Nominees for Election as Directors,” “Committees of the Board of Directors,” and “Procedure for Recommendation and Nomination of Directors and Transaction of Business at Annual Meeting” to be included in the 2023 Abbott Laboratories Proxy Statement.
+Added: Incorporated herein by reference are “Election of Directors (Item 1 on Proxy Card),” “Committees of the Board of Directors,” and “Procedure for Recommendation and Nomination of Directors and Transaction of Business at Annual Meeting” to be included in the 2024 Abbott Laboratories Proxy Statement.
The 2024 Proxy Statement will be filed on or about March 15, 2024.
50 unchanged sentences
Employees was amended and restated as the Abbott Laboratories 2017 Employee Stock Purchase Plan for Non-U.S.
−Removed: (2) Not included in the table:
−Removed: Jude Medical, Inc.
−Removed: In 2017, in connection with the acquisition of St.
−Removed: Jude Medical, Inc., options outstanding under the St.
−Removed: Jude Medical, Inc.
−Removed: 2007 Stock Incentive Plan, as Amended and Restated (2014) were assumed by Abbott and converted into Abbott options of substantially equivalent value.
−Removed: As of December 31, 2022, 309,043 options remained outstanding under these plans.
−Removed: These options have a weighted average purchase price of $29.61.
−Removed: No further awards will be granted under these plans.
For additional information concerning the Abbott Laboratories 2009 Incentive Stock Program, the Abbott Laboratories 2017 Incentive Stock Program, and the Abbott Laboratories 2017 Employee Stock Purchase Plan for Non-U.S.
25 unchanged sentences
3.1 * Amended and Restated Articles of Incorporation of Abbott Laboratories, filed as Exhibit 3.1 to the Abbott Laboratories Current Report on Form 8-K filed on April 26, 2021.
−Removed: 3.2 * Amended and Restated B y -Laws of Abbott Laboratories, effective as of December 9, 2022, filed as Exhibit 3.1 to the Abbott Laboratories Current Report on Form 8-K filed on December 9, 2022.
+Added: 3.2 * Amended and Restated By-Laws of Abbott Laboratories, effective as of April 28, 2023, filed as Exhibit 3.1 to the Abbott Laboratories Current Report on Form 8-K filed on February 17, 2023.
4.1 * Indenture dated as of February 9, 2001, between Abbott Laboratories and The Bank of New York Mellon Trust Company, N.A.
17 unchanged sentences
4.14 * Form of 4.900% Notes due 2046, filed as Exhibit 4.7 to the Abbott Laboratories Current Report on Form 8-K dated November 22, 2016.
−Removed: 4.15 * Form of 4.900% Notes due 2046, filed as Exhibit 4.7 to the Abbott Laboratories Current Report on Form 8-K dated November 22, 2016.
4.15 * Officers’ Certificate Pursuant to Sections 3.1 and 3.3 of the Indenture with respect to 2.350% Notes due 2019, 2.900% Notes due 2021, 3.400% Notes due 2023, 3.750% Notes due 2026, 4.750% Notes due 2036 and 4.900% Notes due 2046 (including forms of notes), filed as Exhibit 4.22 to the Abbott Laboratories 2016 Annual Report on Form 10-K.
38 unchanged sentences
4.27 * Form of 1.500% Note due 2026 (included in Exhibit 4.2 to the Abbott Laboratories Current Report on Form 8-K dated September 27, 2018).
−Removed: 4.29 * Form of 1.500% Note due 2026 (included in Exhibit 4.2 to the Abbott Laboratories Current Report on Form 8-K dated September 27, 2018).
4.28 * Form of 0.100% Note due 2024 (included in Exhibit 4.2 to the Abbott Laboratories Current Report on Form 8-K dated November 19, 2019).
10 unchanged sentences
10.4 * Abbott Laboratories Supplemental Pension Plan, as amended and restated, filed as Exhibit 10.4 to the 2014 Abbott Laboratories Annual Report on Form 10-K.**
−Removed: 10.5 * 1986 Abbott Laboratories Management Incentive Plan, as amended and restated, filed as Exhibit 10.5 to the 2014 Abbott Laboratories Annual Report on Form 10-K.**
−Removed: 10.6 * 1998 Abbott Laboratories Performance Incentive Plan, as amended, filed as Exhibit 10.6 to the 2014 Abbott Laboratories Annual Report on Form 10-K.**
+Added: 10.5 1986 Abbott Laboratories Management Incentive Plan, as amended and restated.**
+Added: 10.6 1998 Abbott Laboratories Performance Incentive Plan, as amended and restated.**
10.7 * Rules for the 1998 Abbott Laboratories Performance Incentive Plan, as amended and restated, filed as Exhibit 10.7 to the 2012 Abbott Laboratories Annual Report on Form 10-K.**
10.8 * Abbott Laboratories 2009 Incentive Stock Program, as amended and restated, filed as Exhibit 10.9 to the 2014 Abbott Laboratories Annual Report on Form 10-K.**
−Removed: 10.9 * Abbott Laboratories 2017 Incentive Stock Program (incorporated by reference to Exhibit B of Abbott’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 17, 2017).**
−Removed: 10.10 * Abbott Laboratories Non-Employee Directors’ Fee Plan, as amended and restated, filed as Exhibit 10.10 to the 2016 Abbott Laboratories Annual Report on Form 10-K.**
+Added: 10.9 Abbott Laboratories 2017 Incentive Stock Program, as amended and restated.**
+Added: 10.10 * Abbott Laboratories Non-Employee Directors’ Fee Plan, as amended and restated, filed as Exhibit 10.1 to the Abbott Laboratories Quarterly Report on Form 10-Q for the period ended March 31, 2023.**
10.11 * Form of Non-Employee Director Restricted Stock Unit Agreement under Abbott Laboratories 1996 Incentive Stock Program, filed as Exhibit 10.2 to the Abbott Laboratories Current Report on Form 8-K dated December 10, 2004.**
45 unchanged sentences
10.57 * Form of Agreement Regarding Change in Control by and between Abbott Laboratories and its named executive officers, filed as Exhibit 10.1 to the Abbott Laboratories Current Report on Form 8-K dated November 30, 2012.**
−Removed: 10.58 * Form of Extension of Agreement Regarding Change in Control by and between Abbott Laboratories and its named executive officers , extending the agreement term to December 31, 2022, filed as Exhibit 10.66 to the 2020 Abbott Laboratories Annual Report on Form 10-K.**
−Removed: 10.59 Form of Extension of Agreement Regarding Change in Control by and between Abbott Laboratories and its named executive officers, extending the agreement term to December 31, 2024.**
+Added: 10.58 * Form of Extension of Agreement Regarding Change in Control by and between Abbott Laboratories and its named executive officers, extending the agreement term to December 31, 2024 , filed as Exhibit 10.59 to the 202 2 Abbott Laborato ries Annual Report on Form 10-K .**
10.59 * Form of Time Sharing Agreement between Abbott Laboratories Inc.
17 unchanged sentences
10.64 * Abbott Overseas Managers Pension Plan, as amended and restated, filed as Exhibit 10.74 to the 2020 Abbott Laboratories Annual Report on Form 10-K.**
−Removed: 10.66 * Five Year Credit Agreement, dated as of November 12, 2020, among Abbott Laboratories, as borrower, various financial institutions, as lenders, and JPMorgan Chase Bank, N.A., as administrative agent, filed as Exhibit 10.75 to the 2020 Abbott Laboratories Annual Report on Form 10-K.
+Added: 10.65 Five Year Credit Agreement, dated as of January 29, 2024, among Abbott Laboratories, as borrower, various financial institutions, as lenders, and JPMorgan Chase Bank, N.A., as administrative agent.
21 Subsidiaries of Abbott Laboratories.
7 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: 97 Abbott Laboratories Dodd-Frank Clawback Policy.
101 The following financial statements and notes from the Abbott Laboratories Annual Report on Form 10-K for the year ended December 31, 2023 filed on February 16, 2024, formatted in Inline XBRL:
22 unchanged sentences
/s/ ROBERT B.
−Removed: FORD /s/ ROBERT E.
−Removed: Ford Robert E.
+Added: FORD /s/ PHILIP P.
+Added: Ford Philip P.
Chairman of the Board and Chief Executive Officer,
and Director of Abbott Laboratories
−Removed: (principal executive officer) Executive Vice President, Finance
+Added: (principal executive officer) Senior Vice President, Finance
and Chief Financial Officer
(principal financial officer)
−Removed: /s/ PHILIP P.
Vice President, Finance and Controller
12 unchanged sentences
Director of Abbott Laboratories Director of Abbott Laboratories
−Removed: /s/ NANCY MCKINSTRY /s/ WILLIAM A.
−Removed: Nancy McKinstry William A.
+Added: /s/ NANCY MCKINSTRY /s/ MICHAEL G.
+Added: Nancy McKinstry Michael G.
Director of Abbott Laboratories Director of Abbott Laboratories
3 unchanged sentences
Director of Abbott Laboratories Director of Abbott Laboratories
−Removed: STRATTON /s/ GLENN F.
−Removed: Stratton Glenn F.
−Removed: Director of Abbott Laboratories Director of Abbott Laboratories
+Added: Director of Abbott Laboratories
ABBOTT LABORATORIES AND SUBSIDIARIES
11 unchanged sentences
Report of Independent Registered Public Accounting Firm
−Removed: To the Shareholders and Board of Directors of Abbott Laboratories
−Removed: Opinion on the Financial Statement Schedule
+Added: To the Shareholders and the Board of Directors of Abbott Laboratories
We have audited the consolidated financial statements of Abbott Laboratories and subsidiaries (the Company) as of December 31, 2023 and 2022, for each of the three years in the period ended December 31, 2023, and have issued our report thereon dated February 16, 2024 (included elsewhere in this Annual Report on Form 10-K).
7 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.